| Title |
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|
|---|---|
| Published in |
Nature Reviews Clinical Oncology, August 2018
|
| DOI | 10.1038/s41571-018-0075-2 |
| Pubmed ID | |
| Authors |
Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim, Julie C. Fitzgerald, Agne Taraseviciute, Catherine M. Bollard, Priti Tewari, Christine Duncan, Chani Traube, David McCall, Marie E. Steiner, Ira M. Cheifetz, Leslie E. Lehmann, Rodrigo Mejia, John M. Slopis, Rajinder Bajwa, Partow Kebriaei, Paul L. Martin, Jerelyn Moffet, Jennifer McArthur, Demetrios Petropoulos, Joan O’Hanlon Curry, Sarah Featherston, Jessica Foglesong, Basirat Shoberu, Alison Gulbis, Maria E. Mireles, Lisa Hafemeister, Cathy Nguyen, Neena Kapoor, Katayoun Rezvani, Sattva S. Neelapu, Elizabeth J. Shpall |
X Demographics
The data shown below were collected from the profiles of 85 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 19 | 22% |
| United Kingdom | 4 | 5% |
| France | 4 | 5% |
| India | 3 | 4% |
| Japan | 2 | 2% |
| Greece | 2 | 2% |
| Germany | 2 | 2% |
| Kenya | 2 | 2% |
| Switzerland | 2 | 2% |
| Other | 12 | 14% |
| Unknown | 33 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 60 | 71% |
| Practitioners (doctors, other healthcare professionals) | 11 | 13% |
| Scientists | 8 | 9% |
| Science communicators (journalists, bloggers, editors) | 6 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 292 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 292 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 43 | 15% |
| Researcher | 41 | 14% |
| Student > Ph. D. Student | 26 | 9% |
| Student > Doctoral Student | 22 | 8% |
| Student > Master | 19 | 7% |
| Other | 47 | 16% |
| Unknown | 94 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 94 | 32% |
| Biochemistry, Genetics and Molecular Biology | 25 | 9% |
| Immunology and Microbiology | 17 | 6% |
| Agricultural and Biological Sciences | 13 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 4% |
| Other | 30 | 10% |
| Unknown | 100 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 118. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2024.
All research outputs
#362,223
of 25,826,146 outputs
Outputs from Nature Reviews Clinical Oncology
#68
of 2,366 outputs
Outputs of similar age
#7,598
of 341,892 outputs
Outputs of similar age from Nature Reviews Clinical Oncology
#4
of 39 outputs
Altmetric has tracked 25,826,146 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,366 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,892 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.